Purpose: A phase III randomised trial was conducted in patients with non-metastatic unresectable non-small-cell lung cancer in order to compare, in responders to induction chemotherapy, consolidation treatment by further chemotherapy to chest irradiation.
Introduction
Chemotherapy in association with definitive-dose thoracic radiotherapy is recommended as the standard treatment for locally advanced, surgically unresectable stage III non-small-cell lung cancer [1] . Indeed, multiple randomised trials have shown that chemotherapy could significantly improve survival when administered before chest irradiation over that achieved by radiotherapy alone [2] [3] [4] [5] [6] [7] [8] [9] . All but one of these trials using a combination of ifosfamide and vindesine [7] investigated cisplatinbased regimens. Some other trials showed no significant difference in survival but they used a non-cisplatincontaining regimen [10] or included a too-limited number of patients to allow meaningful statistical tests [11] [12] [13] . A meta-analysis including all of the studies comparing chemoradiotherapy to irradiation alone has shown an overall reduction in the risk of death by the addition of chemotherapy [14] .
If there is a consensus [1] that chemotherapy improves results obtained by chest irradiation alone, the exact role of radiotherapy has not been well established by randomised trials in terms of survival improvement. Two randomised trials [15, 16] compared chemotherapy and radiotherapy as single-treatment modality and showed similar survivals but both may be criticised. In the first [15] , a moderate dose of radiotherapy was used (42 Gy) , and in the second [16] , the chemotherapy consisted of a single-agent regimen with vindesine. Another design for determining the role of chest irradiation was used by a Japanese group [17] who randomized patients who had no progressive tumour after two courses of a cisplatin-containing chemotherapy randomised between chest irradiation and no further therapy. They obtained a significant survival improvement with the chest irradiation but their trial can also be criticised on grounds that its design was not realistic. In instances of response to two courses of chemotherapy, physicians who do not prescribe irradiation will often continue the treatment by administering further cycles of chemotherapy.
All of these considerations led the European Lung Cancer Working Party (ELCWP) to conduct a randomised trial in patients with initially unresectable nonmetastatic non-small-cell lung cancer (NSCLC). The primary endpoint was to determine if loco-regional irradiation after a cisplatin-based chemotherapy would prolong survival for responding patients in comparison to the treatment by further chemotherapy alone. Secondary endpoints were: the activity of the chemotherapy regimen (MIP: mitomycin C, ifosfamide, cisplatin) in loco-regional NSCLC, the local control rate obtained when irradiation was added to chemotherapy, the role of irradiation as salvage therapy of chemotherapy, the feasibility and frequency of surgical resection after chemotherapy in patients whose NSCLC was initially considered unresectable. The purpose of this paper is to report the results of the primary endpoint.
Patients and methods
Patients with histologically-proven NSCLC had to fulfil all of the following criteria to enter this study: initially unresectable non-metastatic tumour without homolateral malignant pleural effusion, no prior history of malignancy except for non-melanoma skin cancer or in situ carcinoma of the cervix; no prior chemotherapy, surgery or irradiation: age ^ 75 years; Karnofsky performance status 3= 60; good renal (serum creatinine level $1.5 mg/dl), hepatic (serum bilirubin level =£1.5 mg/dl) and haematological (WBC count 5:4,000 /ul and platelet count > 100,000/^1) functions; no recent (<3 months before the date of treatment) myocardial infarction and no active congestive heart failure or cardiac arrhythmia requiring medical treatment; no uncontrolled infectious disease or other serious medical or psychiatric illness precluding adherence to the study protocol. Patients could not be candidates for early irradiation (e.g., because of spine invasion), they had to be accessible for follow-up and had to have provided their informed consent. The protocol had to be approved by the respective ethics committee of the institutions.
After registration with the ELCWP data centre, eligible patients received three courses of MIP chemotherapy (mitomycin C 6 mg/m 2 ; ifosfamide 3 g/m 2 ; cisplatin 50 mg/m 2 ). Mitomycin C was given as a bolus followed by ifosfamide infused over three hours. Cisplatin was administered over one hour, three hours after the end of the ifosfamide infusion. Mesna (1 g/m 2 three hours infusion together with ifosfamide, followed by 500 mg/m 2 bolus at times four and eight hours) was provided to avert urotoxicity and the recommended antiemetic regimen was a combination of lorazepam, metoclopropamide and dexamethasone, according to the initial Cullen publication [19] . Courses were repeated every three to four weeks, as soon as haematological (WBC >4000/mm ? and platelets > 100000/mm 3 ) and renal (serum creatinine <1.5 mg/dl) functions had recovered. If a delay between two courses was longer than five weeks, the patient went off treatment. If the WBC nadir was < 1000/mm 3 and/or platelet nadir <25000/mm 3 , the ifosfamide and mitomycin C dosage for the next course was reduced to 50%. If the serum creatinine peak increased between 1.5 and 2.5 mg/dl. the cisplatin dosage was reduced to 50%. If it was > 2.5 mg/dl. cisplatin was discontinued.
Evaluation of tumour response was performed in week 9 (later if chemotherapy had to be delayed because of haematological toxicity). If the tumour became resectable, surgery was performed followed by mediastinal irradiation. In instances of objective response, the patient was randomised between chest irradiation (60 Gy over six weeks with 2 Gy daily fractions to the primary tumour and the known area of lymph node involvement) or three further courses of MIP chemotherapy. Randomisation at the central data centre using a minimisation technique was stratified according to initial TNM staging, histological subtype and centre. In instances of stable disease or local progression without occurrence of distant metastases, the patient received chest irradiation. If the patient developed distant metastases. he went off treatment.
Chest irradiation should start between three to five weeks after the last chemotherapy administration and after full haematological recovery. In instances of thoracotomy, it should begin within six weeks after surgery. Megavoltage equipment was used and CT scan-based treatment planning was mandatory. The initial volume should include, as determined before chemotherapy, the complete extent of the initial lung tumour with a safety margin of 2 cm of normal lung, the ipsilateral hilum and mediastinal lymph nodes. It should always cover the ipsilateral hilum and the mediastinum from the thoracic inlet down to 5 cm below the carina. The inferior mediastinal nodes were included only in instances of lower lobe lesions and the supraclavicular nodes in instances of upper lobe lesions, positive high mediastinal nodes or if they were involved. After the first 45 Gy, the cone down volume included the area of tumour involvement with a minimal 1 cm safety margin. Deliverance of doses in excess of 45 Gy to the spinal cord and the whole heart was avoided. In instances of positive mediastinal lymph nodes, adequate oblique fields were recommended. A total dose of 60 Gy had to be given in six weeks with daily 2 Gy fractions (five per week). For the first part of the treatment, the dose that should not exceed 45 Gy was specified on the central axis. For the second part, it was specified at the isocentre in the central plane. The isodose encompassing the target volume should not be less than 56 Gy. If performed after surgery, the target volume included the ipsiiateral hilum including the bronchial stump with a 2 cm margin of uninvolved pulmonary tissue, the entire mediastinum from the suprasternal notch to not less than 5 cm below the carina and across the trachea to include I cm of contralateral lung and, in instances of lower lobe tumours, inferior mediaslinal nodes.
The initial work-up consisted of a complete history and physical examination with weight, height and surface area measurements; recording of performance status; fiberoptic bronchoscopy with biopsy, chest X-ray and CT scan; bone scintigraphy with X-ray of suspected lesions; liver and adrenals CTscan or echography; brain CTscan; blood chemistries including complete blood cell count, electrolytes, serum creatinine, and liver function tests; EKG and pulmonary function tests. Except for bulky involvement, mediastinoscopy with biopsy was recommended prior to chemotherapy to confirm mediastinal dissemination and unresectability. Blood chemistries, chest X-ray and clinical examination were repeated before each new course. Restaging with all of the tests performed during the initial work-up was repeated after the first three courses of chemotherapy, except mediastinoscopy, and for the responders, at the end of therapy. After treatment discontinuation, patients were examined with biological tests and chest X-ray every two months for the first six months and thereafter every three months. A complete work-up was recommended every six months.
Patients were evaluated for response after completion of three courses of chemotherapy. Response status, as well as the initial TNM stage, was evaluated during regular meetings of the group by at least three independent observers. Complete remission (CR) was defined as the disappearance of all signs of disease. Partial response (PR), in measurable disease, was defined as a 50% or greater decrease of the total tumour load, without the appearance of new lesions or progression of any lesion. The tumour load was estimated as the tumour area calculated by the multiplication of the longest diameter by the greatest perpendicular diameter. In assessable disease. PR was defined as an estimated decrease in tumour size of 50% or more. Progression (PG) was considered to be an increase of greater than 25% in one or more measurable or assessable lesions or the appearance of a new lesion. All other circumstances were classified as no change (NC). Patients with early death (ED) due to PG before evaluation, those with toxic death due to chemotherapy, or those with early chemotherapy discontinuation because of toxicity were considered as treatment failures and were assessable for response. Survival and response duration were measured from the date of registration. WHO criteria were used to assess toxicity The primary endpoint of the trial was to determine if locoregional irradiation after three courses of MIP chemotherapy would prolong the survival of responding patients with unresectable non-metastatic NSCLC in comparison to treatment by three further courses of MIP chemotherapy without irradiation. To detect an increase from 10% to 25% in the two-year survival rate, 122 responding patients needed to be randomised (a = 0.05; l-(3 = 0.80; one-tailed test) and followed until observation of 104 events.
Overall survival was calculated from the day of registration and, for randomised patients, from the day of randomisation. Survival distributions were estimated by the Kaplan-Meier method. The log-rank test was used to compare survival distributions. />-values (two-tailed) for testing the null hypothesis of the equality of proportions were calculated using Fisher's exact test or a x 2 test. Multivariate analyses for prognostic factors were performed by adjusting the data with Cox models for duration of survival and logistic regression models for objective response, using a backward stepwise method for selection of variables to be retained in the final model. Coefficient estimates were obtained by the maximum likelihood method.
Results
Between December 1989 and February 1996,484 patients were registered in the trial. Twenty-two (4.5%) were ineligible for the following reasons: the existence of distant metastases (seven patients), the presence of another cancer (five patients), incomplete initial work-up (three patients), contra-indication for chest irradiation (two patients) and miscellaneous reasons such as absence of assessable lesion, deafness precluding cisplatin administration, poor Karnofsky PS, initial thrombopenia and renal failure (one patient each). A total of 462 patients were thus eligible for entry into the present trial.
The main characteristics of the eligible patients are listed in Table 1 . Eight percent were female, and the median age was 63 years (range 33-75). Five percent of the patients presented with stages I or II, 45% with stage IIIA and 50% with stage IIIB. There were 21 patients with aT 3 N 0 M 0 tumour. The majority of the patients had good Karnofsky PS (>80: 81%) and no or minimal weight loss (70%; this was unknown for 13% of the patients). Histological types were squamous cell carcinoma in 61%, adenocarcinoma in 20%, large-cell carcinoma in 9% and other non-small-cell lung cancers in 10%. The median follow-up was 55 months, ranging from 0 to 95 months. At the time of analysis, 417 patients were deceased, 45 (10%) were alive and 11 lost to follow-up.
A total of 424 patients were assessable for tumour response after induction by three courses of MIP chemotherapy. Reasons for non-assessability in 38 patients were the following: loss to follow-up (11), protocol violation (10) , no work-up at assessment (two), death prior to chemotherapy administration (two), early death unrelated to cancer or treatment (13) . Early deaths were attributed to lung embolism (two), cerebral stroke (two), lung infection (two), aspergillosis (one), cardiac arrest (one), respiratory failure (one), cardiac failure (one) or unknown (three).
Eighty-nine percent of the eligible patients received three courses of MIP, 6% two and 5% only one. Dosage was reduced in 6.5% and chemotherapy was delayed in 21%. Toxicity was moderate and consisted mainly of alopecia (43% grade 2 or 3), nausea and vomiting (23% grade 2, 7% grade 3 and two patients with grade 4) and haematological depression. Grades 3 and 4 leucopenia and thrombopenia were, respectively, seen in 70 and 16 patients and in 12 and six patients. Grade 3-4 infections were observed in 11 cases and no significant episodes of bleeding due to toxicity occurred.
Objective response was obtained in 161 patients, three of them complete. The OR rate was 38% (95% confidence interval (95% CI): 33-43) in the assessable patients and 35% (95% CI: 30-39) in the eligible patients. No change was documented in 150 patients, including 53 (12.5%) with minor response (decrease < 50%). There were 103 progressions, two early deaths of malignant disease, one toxic death due to febrile neutropenia and seven chemotherapy discontinuations because of excessive toxicity. The overall median survival (MS) time was 43 (95% CI: 39-47) weeks with a 41% (95% CI: 36-46) one-year and a 16% (95% CI: 12-20) two-year survival rates.
One hundred fifteen patients were randomised for consolidation therapy between chest irradiation and further MIP chemotherapy. All were objective responders (one CR was randomised for radiotherapy) but 10 (8.6%) -five per arm -including six with no change (all with minor responses at record review) and four nonassessable (two with incomplete work-up for response Table 2 . The arms were well balanced for the main patient characteristics; 52% had initial stage IIIA disease and 44% stage IIIB. For those randomised to chemotherapy, all but six received the full treatment, the delay between the first days of the third and fourth courses being longer than 45 days in only two patients. No significant toxicity was observed, with 29% and 21% grade 3-4 toxicity, respectively, for leukocytes and platelets. For the 55 patients randomised to chest irradiation, treatment was started before day 45 after the first day of the third course of chemotherapy in 82% of the patients and 78% received 56 Gy according to the treatment plan. Tolerance of chest irradiation was good, the most significantly reported side effect being transient oesophagitis.
At the time of analysis, 104 patients had died and 11 were still alive (seven in the MIP arm and four in the radiotherapy arm) including one who was lost to followup. The median follow-up was 218 weeks, ranging from 29 to 393 weeks. The median interval between initial registration and randomisation was 69 days (range 52- 96) for the chemotherapy arm and 79 days (range 49-97) for the radiotherapy arm (non-significant difference).
As shown in Figure 1 , there was no statistically significant difference {P -0.54) in survival between the two study arms: median survival times from randomisation were, respectively for the chemotherapy and radiotherapy arms, 42 (95% CI: 35-51) and 54 (95% CI: 43-73) weeks with one-year survival rates of 39% (95% CI: 26-52) and 51% (95% CI: 37-68) and two-year survival rates of 18% (95% CI: 8-28) and 22% (95% CI: 11-33). There was also (Table 2) no significant difference among all of the subgroups analysed except for patients with an assessable (not measurable) lesion whose survival was significantly improved in the radiotherapy arm. Table 3 summarises the univariate prognostic factor analysis for survival performed with the randomised patients, revealing as only statistically significant, initial (at registration) Karnofsky PS and platelet count. A Cox model with all of the variables with a P < 0.30 in univariate analysis was applied for multivariate analysis and identified as only significant independent prognostic factor PS (HR 0.36; 95% CI: 0.20-0.64; P = 0.002). The results were similar if the analysis was performed without taking into account weight loss and serum LDH level that have high rates of missing data.
Response median duration (Figure 2 ) was, respectively, 25 (95% CI: 19-29) and 30 (95% CI: 19-39) weeks (P -0.17) for the chemotherapy and radiotherapy arms. At the time of analysis, 48 of the patients in the chemotherapy arm had relapsed: 33 locally, eight distantly and seven at both types of site; 30 of them were treated by chest irradiation and five by chemotherapy. Thirty-nine patients in the irradiation arm relapsed: 16 locally, 15 distantly and eight at both types of site; ten of these received MIP chemotherapy and five other regimens. In each arm, brain metastases were diagnosed in five patients at initial progression.
Actuarial local control duration rate, obtained by considering only local relapse as an event even had distant relapse been documented, was significantly improved Figure 3 ) by chest irradiation: the median duration of local control was, respectively, 31 (95% CI: 24-38) weeks for the MIP arm and 158 (95% CI: 42-not calculable) for the irradiation arm with two-year rates of 24% and 57%. This difference was highly statistically significant (P -0.0007). The distant control duration (Figure 4) , with respective median times and two-year rates of 42 weeks and 20% for MIP and 67 weeks and 26% for radiotherapy, was not statistically different (P -0.30).
Discussion
The results obtained in the present trial lead us to conclude that, for patients with unresectable non-metastatic non-small-cell lung cancer, when an objective response has been obtained by an induction chemotherapy regimen containing cisplatin and ifosfamide, further che- motherapy and chest irradiation do not appear different in terms of survival for consolidation treatment. We will concentrate our discussion on this point, that was the main objective of our trial. As far as we know, the design of our study is unique, which makes direct comparison with other studies im-possible. It adds interesting insights to our present understanding regarding the management of loco-regional NSCLC. This concept can be summarised according to the published studies as following: 1) multiple randomised trials [2] [3] [4] [5] [6] [7] [8] , that have been the object of metaanalyses [14, 18, 19] have demonstrated, with a high level of evidence, that chemotherapy followed by chest irradiation improves survival over radiotherapy alone; 2) the trial by Kubota et al. [17] has shown, with a small number of patients but with a high statistical significance, that chest irradiation increases survival in comparison to no-further-treatment in patients with no disease progression (objective response or no change) after two courses of induction chemotherapy with a cisplatincontaining regimen. Our trial has dealt only with objective responders and is thus not directly comparable to the Kubota study; it is possible that, in the context of its specific therapeutic design, consolidation therapy, whether irradiation or chemotherapy, has no significant effect on survival. The Kubota trial suggests that consolidation therapy has a role but that to demonstrate it formally, the addition of a third arm with no treatment to our randomisation scheme would have been necessary.
According to our results, whether or not to consider chest irradiation as mandatory for the treatment of unresectable non-metastatic NSCLC becomes debatable if chemotherapy is administered. Indeed, despite a better local control rate, a known effect of this treatment modality, radiotherapy has not proven capable of significantly improving survival. Although it will be necessary to perform confirmatory trials, it is noteworthy that the level of evidence in favour of a positive effect of radiotherapy in stage III NSCLC is weak. There is no randomised trial comparing modern irradiation alone to best supportive care, probably because it has become recognized as the classical standard treatment for this disease. However, two randomised trials addressed this question in the 1960s [20] [21] [22] with, respectively, 249 and 554 patients, and failed to show significant survival improvement in the treated group. When in a randomized trial chest irradiation has been directly compared to a weak chemotherapy regimen alone such as single-agent vindesine [16] , no difference in survival has been observed. There is nevertheless a series of uncontrolled studies, well summarised in a recent review [23] reporting in patients with inoperable NSCLC, a five-year survival rate ranging from 4% to 10%. Similar results are reported for the control arms with chest radiotherapy alone in the randomised trials already cited comparing this approach to primary chemotherapy followed by irradiation. These low rates of potential cure have to be considered with caution for at least two important reasons related to the fact that the individual characteristics of the long-term survivors are not reported. Firstly, it is not certain that the patients did not in fact have very small tumours for which elective radiotherapy has been shown to be curative [24] [25] [26] [27] . Secondly, it is not known if salvage therapy like surgery or chemotherapy was performed, since such information is usually not formally reported.
Some aspects of the trial require further discussion because they can be potential sources of bias or at least can be interpreted as such. Our randomisation has only concerned patients with objective responses, even if, for the purpose of the intent-to-treat analysis, we have kept the few patients with no change (in fact responses classified as minor and thus formally as no-change at patient record review) or who were not assessable for response. They represented only a small percentage of the randomised patients (8.6%) and their exclusion from the analysis did not change the results. We could also have considered for randomisation the patients with no change as Kubota did and not proposed a systematic chest irradiation in that situation. In fact, we did not include these patients because in our prior studies, it was unusual to obtain an objective response after three courses in nochange patients by continuing chemotherapy. Moreover, we wanted to offer to these patients at least the potential benefit of local control by radiotherapy.
We were able to randomise only two-thirds of the responders to chemotherapy because some were considered as having become candidates for surgery and others have refused the randomisation, preferring to choose the consolidation therapy themselves. This type of potential bias in the selection of patients for the controlled part of the study cannot be avoided for obvious ethical reasons. Since it was performed before the procedure, it did not create an imbalance between the arms, which was our main concern.
Thirty-two patients, comprising 7% of the eligible patients including 22 responders, were assessable for surgery results. We took into consideration the possible benefit reported in many series including IIIA [28] [29] [30] [31] [32] [33] and/or IIIB [34] [35] [36] and decided that, from an ethical point of view, it would be impossible to fail to perform surgery if chemotherapy seemed to render the disease resectable. As only two randomised patients benefited from this approach, the risk of bias was minimal. Moreover, in a pragmatic approach, this situation may occur in the management of such diseases and it is thus correct to tolerate it in the study. It is indeed interesting to note the small percentage of patients finally affected by secondary surgery.
A small percentage (5%) of the patients in our trial population with stage I or II disease were included because of an incorrect assessment of the clinical TNM by the investigator or because the patient was considered as functionally inoperable. Only four of those participated in the randomisation and three of them were in the radiotherapy arm. This situation is also seen in routine practice and as for the patients who became resectable, we decided to admit them to the study for practical reasons. As their number is very small, it is highly unlikely that they have a significant effect on the results.
In the analysis of subgroups between the randomised arms, we found only one statistically significant test and it was observed in the subgroup of patients with nonmeasurable disease in favour of the radiotherapy arm. We have no explanation for this result other than the possibility that the test result was an inadvertent falsepositive one within the context of the performance of many statistical tests. It should be noted that in the experience of our group no differences have been observed between patients with measurable disease and those with an assessable one, regardless of whether response [37] , overall survival [38] or long-term survival [39] was being considered.
We chose as chemotherapy regimen the association of cisplatin, ifosfamide and mitomycin C (MIP) as defined by Cullen [40] . Cisplatin has been commonly used in the randomised trials investigating the role of chemotherapy in unresectable non-metastatic NSCLC but ifosfamide has been administered in only one published trial [7] and in another one described in an abstract [41] comparing MIP followed by irradiation to irradiation alone. In both trials, the ifosfamide-containing regimen was associated with a better survival than irradiation alone. Moreover, the Wolf trial [7] is the only randomised trial in which a non-cisplatin regimen has had a positive effect on survival in non-metastatic NSCLC. Ifosfamide is one of the standard active drugs for this disease [42] . Our group has recently shown that the addition of ifosfamide to a platinum derivative combination very significantly improves stage IV NSCLC [43] and an Italian collaborative study has demonstrated that the MIP regimen significantly increased survival in advanced NSCLC in comparison to the cisplatin-etoposide one [44] . In view of all these data, MIP can be considered as one of the best regimens for NSCLC and there is no a priori argument to indicate that the use of another chemotherapy regimen would have yielded better results in the context of the study design.
The role of salvage therapy can potentially bias the final study results. Indeed it was proposed that randomised patients at relapse be given chest irradiation if their response had been consolidated by chemotherapy and vice versa. More patients received chest irradiation (n = 30) at this step than chemotherapy (n = 15). If salvage therapy has a significant impact on survival, it may have cancelled a significant benefit of first-line therapy by a crossover effect. However, the non-statistically significant difference in response duration between the two study arms suggests that the anticancer effectiveness in terms of disease control was similar between the two investigated treatments. Of course, the best scientific experimental design would have been to forbid salvage treatment at relapse but this proposal would never be acceptable from an ethical point of view. For such trials, uncertainty with regard to the potential effect of second-line therapies has to be accepted.
The only statistically significant difference observed between the randomised arms was an increased local control rate with chest irradiation, the distant control rate being similar. This result was expected and its implications for routine practice require further evaluation. Indeed, as it was not associated with improved survival, the potential subjective effect for the patient in terms of symptom control and better quality of life has to be investigated by further controlled studies with appropriate design and methodology. The potential subjective detrimental effect of radiation pneumonitis should also be taken into account in the endpoint analysis.
In conclusion, our randomised controlled trial has shown that for patients with unresectable non-metastatic NSCLC, after induction chemotherapy with a cisplatinand ifosfamide-containing regimen, consolidation therapy by chest irradiation or further chemotherapy has statistically similar effects on survival but a better local control duration rate has been observed with radiotherapy. These data have potential important implications for the role of chest irradiation in the management of stage III NSCLC and confirmatory trials conducted by other groups would be helpful. Further investigations should clarify the benefit, for the patient, of the local control of the disease obtained by radiotherapy, and examine other induction chemotherapy regimens including evaluation of the roles of drug dosages and of new drugs and also the effect of concurrent induction chemoradiotherapy as opposed to chemotherapy alone.
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